Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Minimal By Design: Define MSE Endpoints
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
When to Begin FcRn: Initiation Criteria, Key Evidence
Escalate With Intention: Stepwise, Target-Anchored Moves
The IgG Clock: Redose Using IgG Kinetics
Shared Goals, Shared Gains: Align With Patient Preferences
Not Just a Headache: Migraine Across Women’s Lifespan
Jelena Pavlović, MD, PhD
Amaal J. Starling, MD, FAHS, FAAN
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG
Linda Bradley, MD
Samantha Denäe
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
Melissa Simon, MD
Casey Joe Hinds
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Strategies to Address Healthcare Disparities in Patients With Endometriosis
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Alloimmune Thrombocytopenia in the Fetus and Newborn
James B. Bussel, MD
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.